Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
McKesson's Capital Expenditure for the
three
months ended in Dec. 2023 was $-154.00 Mil. Its Revenue for the
three
months ended in Dec. 2023 was $80,898.00 Mil.
Hence, McKesson's Capex-to-Revenue for the
three
months ended in Dec. 2023 was 0.00.
McKesson Capex-to-Revenue Historical Data
The historical data trend for McKesson's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of McKesson's Capex-to-Revenue
For the Medical Distribution subindustry, McKesson's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
McKesson's Capex-to-Revenue Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, McKesson's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where McKesson's Capex-to-Revenue falls into.
McKesson Capex-to-Revenue Calculation
McKesson's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
McKesson (NYSE:MCK) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
McKesson Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of McKesson's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
McKesson Corp is one of three leading pharmaceutical wholesalers in the U.S. engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the U.S. pharmaceutical wholesale industry. Outside the U.S. market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCK has been successfully added to your 